0.2158
Schlusskurs vom Vortag:
$0.2212
Offen:
$0.2217
24-Stunden-Volumen:
1.19M
Relative Volume:
0.19
Marktkapitalisierung:
$10.41M
Einnahmen:
$40,400
Nettoeinkommen (Verlust:
$-9.18M
KGV:
-0.804
EPS:
-0.2684
Netto-Cashflow:
$-5.78M
1W Leistung:
+0.75%
1M Leistung:
-10.86%
6M Leistung:
-79.35%
1J Leistung:
-85.32%
Jupiter Neurosciences Inc Stock (JUNS) Company Profile
Firmenname
Jupiter Neurosciences Inc
Sektor
Branche
Telefon
(561) 406-6154
Adresse
1001 NORTH US HWY 1, JUPITER
Compare JUNS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
JUNS
Jupiter Neurosciences Inc
|
0.2158 | 10.67M | 40,400 | -9.18M | -5.78M | -0.2684 |
|
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
919.94 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Jupiter Neurosciences Inc Aktie (JUNS) Neueste Nachrichten
Jupiter Neurosciences appoints Tomas Philipson to board - Investing.com
Jupiter Neurosciences Strengthens Board with Appointment of Dr. Tomas J. Philipson - GlobeNewswire
Price to book forward of Jupiter Neurosciences, Inc. – NASDAQ:JUNS - TradingView
JUNS Q4 2025 Earnings: EPS Beat Offers Optimism Despite No RevenueRevenue Warning Signal - dars.gov.et
Jupiter Neurosciences, Inc. Files Form 8-K: Nasdaq Listed Emerging Growth Company Overview - Minichart
Jupiter Neurosciences Adds Economist Philipson to Board - TipRanks
Jupiter Neurosciences | 424B3: Prospectus - Moomoo
Market Movers | Winners: TRNR, DCOY, ATLN | Losers: BJDX, EVMN, CELZ - Trefis
Let's uncover which stocks are experiencing notable gaps during today's session. - ChartMill
A Tiny Psychedelic Stock Just Exploded Over 50% – Retail Traders Think $1 Is Next - Stocktwits
Top Premarket Decliners - Moomoo
Get insights into the top gainers and losers of Monday's pre-market session. - ChartMill
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Universe Pharmaceuticals Shares Are Trading Higher By Around 228%; Here Are 20 Stocks Moving Premarke - Benzinga
Form S-1 Jupiter Neurosciences Inc For: 26 June By Investing.com - Investing.com Nigeria
Jupiter Neurosciences files for resale of up to 16M shares by Yorkville - scanx.trade
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
JUNS stock sees best single-day gains in almost a year on $100M MDMA drug licensing deal – retail expects shares to hit $1 - MSN
Friday's after hours session: top gainers and losers - ChartMill
Jupiter NeurosciencesFiles For Resale Of Up To 16 Million Shares By Selling StockholderSEC Filing - TradingView
Yorkville to resell 16M Jupiter Neurosciences (NASDAQ: JUNS) shares under SEPA - Stock Titan
Jupiter Neurosciences, Inc. Actuals & Estimates (NASDAQ:JUNS) - TradingView
JUNSJupiter Neurosciences Inc Earnings - Finviz
Form DEF 14A Jupiter Neurosciences Inc For: 22 June By Investing.com - Investing.com Nigeria
[ARS] JUPITER NEUROSCIENCES, INC. SEC Filing - Stock Titan
Form 8K Jupiter Neurosciences Inc For: 22 June By Investing.com - Investing.com Nigeria
Jupiter Neurosciences director Allison W. Brady resigns from board By Investing.com - Investing.com Nigeria
Jupiter Neurosciences Announces Board Member Resignation and Vacancy - TipRanks
Jupiter Neurosciences director Allison W. Brady resigns from board - Investing.com
Jupiter Neurosciences (JUNS) seeks reverse split and larger equity plan - Stock Titan
Jupiter Neurosciences, Inc. Announces CEO Change in Nasdaq Filing – 8-K SEC Report June 2026 - Minichart
Allison Brady resigns from Jupiter Neurosciences Board (NASDAQ: JUNS) - Stock Titan
Allison W. Brady resigns from Jupiter Neurosciences board and committees - TradingView
Director Allison W. Brady resigns from Jupiter Neurosciences (NASDAQ: JUNS) board - Stock Titan
Jupiter Neurosciences Inc (JUNS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jupiter Neurosciences Inc (JUNS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Jupiter Neurosciences Inc (JUNS) Institutional Confidence - TradingKey
Jupiter Neurosciences Inc (JUNS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jupiter Neurosciences Inc (JUNS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jupiter Neurosciences Inc (JUNS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jupiter Neurosciences Inc (JUNS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jupiter Neurosciences Inc (JUNS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Jupiter Neurosciences Inc (JUNS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Reunion Neuroscience Announces Appointment of Sahil V. Kirpekar, M.D., as President and CEO - Yahoo Finance
Jupiter Neurosciences Inc. (JUNS) Q4 2025 Earnings: Narrower-than-expected loss highlights clinical pipeline progress - newsline.com
JUNS Q4 2025 Earnings: Narrower Loss Per Share Surpasses Estimates Amid No Revenue - newsline.com
Jupiter stock soars after $100 million ALA-002 licensing deal - MSN
Jupiter Neurosciences (JUNS) proposes 5.25M-plan increase and 1:10–1:100 reverse split - Stock Titan
Finanzdaten der Jupiter Neurosciences Inc-Aktie (JUNS)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):